Mohini Ranganathan

Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis

Deepak Cyril D’Souza, Mohini Ranganathan, Gabriel Braley et al. · Neuropsychopharmacology · 2008 · 258 citations · Full text

Cannabis Use, Psychoactive Drug, Psychiatry +14

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

Douglas L. Boggs, Toral Surti, Aarti Gupta et al. · Psychopharmacology · 2018 · 224 citations

Cannabis Use, Psychopathology, Psychiatry +13

Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis

Deepak Cyril D’Souza, Jose Cortes-Briones, Mohini Ranganathan et al. · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · 2015 · 204 citations · Full text

Cannabis Use, Substance Abuse, Health Sciences +10

Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial

Deepak Cyril D’Souza, Jose Cortes-Briones, Gina Creatura et al. · The Lancet Psychiatry · 2018 · 183 citations

Cannabis Use, Substance Abuse, Substance Use +12

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin

Chadi G. Abdallah, Lynnette A. Averill, Ralitza Gueorguieva et al. · Neuropsychopharmacology · 2020 · 171 citations · Full text